PLANNING AND EVALUATION (Core-453) ABSTRACT Overview: The University of Colorado Cancer Center's (UCCC) Planning and Evaluation (P&E) activities, under the leadership of Dan Theodorescu MD PhD, are focused on the comprehensive strategic review of the UCCC and its Research Programs, Shared Resources (SRs), Clinical Research, and associated operations to ensure the optimization of UCCC's activities and the recognition and pursuit of particular opportunities. The P&E component is conducted in a multi-faceted approach that includes the review and assessment by the External Advisory Board (EAB), several key internal advisory committees, and the Senior Leadership of the UCCC. These activities are augmented by specific ad hoc individual and group external reviewers along with key input from UCCC members through UCCC organizational structures. Following the NCI Site Visit of the UCCC in June 2011 and receipt of the detailed CCSG review, UCCC Senior Leadership and Research Program Leaders initiated a series of meetings to identify key areas for development and recruitment in addition to those strategic directions outlined in the Director's Overview. Key areas were identified as recruitment of an Associate Director for Population Sciences Research, the reconstruction of the Protocol Review and Monitoring System (PRMS) which had been disapproved and implementation of better educational opportunities and infrastructure (new clinical trial management system (CTMS)) in support of clinical investigation. The UCCC External Advisory Board (EAB) played a critical role in this strategic planning and evaluation activities through annual visits and written feedback. Accomplishments: Since 2011 such P&E activities have led to the successful accomplishments of many of the strategic directions outlined in the Director's Overview in addition to the key areas outlined above. In the next funding period, the P&E component proposes the following Specific Aims: 1) Creation of appropriate external and internal advisory bodies to ensure strategic development, expert guidance, and rigorous review of UCCC research programs and activities; and 2) Development of processes for continuous review and improvement of UCCC programs to ensure efficiency, effectiveness, and concordance with UCCC strategic initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-30
Application #
9429046
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications